Video

Surgical decision-making in the era of MIGS

Author(s):

OT Staff Reports

Kuldev Singh, MD, MPH, professor/director of the Glaucoma Service Stanford Medical Center, shares the highlights from his discussion on surgical procedure decision-making in the era of MIGS.

See more Glaucoma 360 coverage

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants
March 23rd 2025

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US
March 18th 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025
March 17th 2025

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025

© 2025 MJH Life Sciences

All rights reserved.